OncLive Polls Show Top Votes for Anticipated Gynecologic Cancer Abstracts at ASCO 2025

Ovarian Cancer | Image
Credit: © Sebastian Kaulitzki
– stock.adobe.com

Ahead of the 2025 ASCO Annual Meeting, which officially kicks off on May 30, discussions about top abstracts, sessions, and insights flooded feeds on social media among gynecologic oncologists. To identify the most anticipated data and presentations, OncLive® initiated 2 informal social media polls for gynecologic oncologists on X and LinkedIn.

Of note, 56% of 16 respondents and 50% of 10 respondents on LinkedIn and X, respectively, selected the phase 3 KEYNOTE-A18 trial (NCT04221945) as the most highly anticipated abstract; this study is evaluating pembrolizumab (Keytruda) plus chemotherapy for the treatment of patients with high-risk, locally advanced cervical cancer. Coming in second place on both platforms was the phase 3 ROSELLA trial (NCT05257408) investigating relacorilant plus nab-paclitaxel (Abraxane) in advanced platinum-resistant ovarian cancer, with votes from 40% and 31% of respondents on X and LinkedIn, respectively. On both platforms, the remaining votes went to the phase 3 FIRST (NCT03602859; X, 10%; LinkedIn, 6%) and CALLA (NCT03830866; 0%; 6%) trials.

In a separate poll, clinicians were asked about which gynecologic cancer subtype they thought would have the most potentially practice-changing research during the meeting. Poll results on both X and LinkedIn demonstrated similar trends. Specifically on X, 51.7% of 29 total respondents voted for ovarian cancer, 34.5% voted for endometrial cancer, 13.8% voted for cervical cancer, and no respondents voted for vulvar cancer. On LinkedIn, these results among 176 respondents were ovarian cancer (52%), endometrial cancer (32%), and cervical cancer (16%), with no votes for vulvar cancer.

Following votes from both polls, OncLive highlighted select anticipated abstracts being presented at the 2025 ASCO Annual Meeting.

LBA5504: Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.

Session time: Monday, June 2, 9:12-9:24 AM CDT

KEYNOTE-A18 evaluated pembrolizumab plus chemoradiotherapy vs placebo plus chemoradiotherapy in patients with newly diagnosed, high-risk, locally advanced cervical cancer.1 The randomized, placebo-controlled, double-blind study included 1060 patients, in which 529 and 531 patients were randomly assigned to the pembrolizumab and placebo arms, respectively. Patients were treated with either 5 cycles of pembrolizumab at 200 mg or placebo every 3 weeks plus chemoradiotherapy, which was followed by 15 cycles of pembrolizumab at 400 mg or placebo every 6 weeks. The primary end points of the study were progression-free survival (PFS) per RECIST 1.1 criteria and overall survival (OS).

In January 2024, the FDA approved pembrolizumab with chemoradiotherapy for FIGO 2014 stage III to IVA cervical cancer, which was supported by data from the KEYNOTE-A18 study.2

Notably, previously reported data from the second interim analysis presented at the 2025 SGO Annual Meeting on Women’s Cancer in March revealed that the median OS was not reached in the pembrolizumab or placebo arms.3 The OS rates at 36 months were 82.6% (95% CI, 78.4%-86.1%) compared with 74.8% (95% CI, 70.1%-78.8%), respectively.

LBA5507: ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel vs nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).

Session time: Monday, June 2, 10:00-10:12 AM CDT

The ROSELLA study assessed relacorilant plus nab-paclitaxel in patients with advanced platinum-resistant ovarian cancer.4 The randomized, global multicenter, open-label study enrolled 381 patients at approximately 125 global sites.4,5 Patients on the study were randomly assigned to receive relacorilant plus nab-paclitaxel or nab-paclitaxel monotherapy. Those in the combination arm were treated with oral relcorilant at 150 mg once daily with food for 3 consecutive days.4 Intravenous nab-paclitaxel was administered at 80 mg/m2 on days 1, 8, and 15 of each 28-day cycle. Furthermore, patients in the monotherapy arm were treated with nab-paclitaxel at 100 mg/m2 on days 1, 8, and 15 of each 28-day cycle. The primary end point was PFS by blinded independent central review (BICR); secondary end points included OS, investigator-assessed PFS, objective response rate, best overall response, duration of response, and clinical benefit rate at 24 weeks.

Data from the primary analysis of the study announced in Marchdetermined that the trial met its primary end point. Relacorilant plus nab-paclitaxel reduced the risk of disease progression or death by 30% compared with those treated with nab-paclitaxel monotherapy (HR, 0.70; P = .008).6 The median PFS by BICR was 6.5 months vs 5.5 months in the combination and monotherapy arms, respectively. Additionally, at an interim evaluation of OS, patients treated with the combination had a median OS of 16.0 months vs 11.5 months for nab-paclitaxel alone.

LBA5506: FIRST/ENGOT-OV44: a phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC).

Session time: Monday, June 2, 9:48-10:00 AM CDT

The phase 3 FIRST study evaluated dostarlimab-gxly (Jemperli) combined with niraparib (Zejula) as first-line treatment in patients with stage III or IV non-mucinous epithelial ovarian cancer.7 The randomized, double-blind study enrolled 1402 patients, who were randomly assigned to receive either standard of care (SOC; carboplatin/paclitaxel with or without bevacizumab) plus placebo, SOC plus niraparib, or SOC plus dostarlimab/niraparib.8 The primary end point of the study was PFS per RECIST 1.1 criteria.

In December 2024, it was announced that the study met its primary end point, which demonstrated a statistically significant difference in the dostarlimab/niraparib arm compared with SOC plus niraparib with or without bevacizumab.9 However, the key secondary end point of OS was not statistically significant between the arms.

Abstract 5502: Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): phase 3 CALLA trial analyses.

Session time: Monday, June 2, 8:48-9:00 AM CDT

Previously reported data from CALLA showed that the addition of durvalumab (Imfinzi) to chemoradiation did not lead to a significant improvement in PFS vs chemoradiation alone in patients with locally advanced cervical cancer.10 At ASCO, investigators will present data from a preplanned analysis evaluating the correlation between circulating tumor DNA and relapse/survival in patients treated during the study.11

During the study, patients at least 18 years of age with stage IB2 to IIB, node-positive cervical cancer; or IIIA to IVA disease irrespective of node status were randomly assigned 1:1 to receive durvalumab plus concurrent chemoradiation or chemoradiation alone. The ctDNA anaylsis was conducted using the NeXT Personal ultrasensitive, tumor-informed minimal residual disease assay. Samples were collected at baseline, day 1 of cycle 3, and 6 months following the start of treatment.

Want to learn more about why these abstracts are generating buzz? Check out this preview article featuring exclusive expert insights and visit our conference coverage page for real-time updates on these presentations and more throughout the meeting.

References

1. Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403(10434):1341-1350. doi:10.1016/S0140-6736(24)00317-9
2. FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 stage III-IVA cervical cancer. FDA. January 12, 2024. Accessed May 29, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemoradiotherapy-figo-2014-stage-iii-iva-cervical-cancer
3. Duska LR, Xiang Y, Hasegawa K, et al. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: overall survival and progression-free survival 2 results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO). Seattle, WA; March 14-17, 2025.
4. Olawaiye AB, Kim JW, Bagameri A, et al. Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer. J Gynecol Oncol. 2024;35(4):e111. doi:10.3802/jgo.2024.35.e111
5. Relacorilant in combination with nab-paclitaxel in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer. ClinicalTrials.gov. Updated April 16, 2025. Accessed May 29, 2025. https://clinicaltrials.gov/study/NCT05257408
6. Primary endpoint met in Corcept’s pivotal phase 3 ROSELLA trial of relacorilant in patients with platinum-resistant ovarian cancer. March 31, 2025. Accessed May 29, 2025. https://ir.corcept.com/news-releases/news-release-details/primary-endpoint-met-corcepts-pivotal-phase-3-rosella-trial
7. Hardy-Bessard A-C, Moore KN, Mirza MR, et al. ENGOT-OV44/FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first-line treatment of stage 3/4 non-mucinous epithelial ovarian cancer (OC). J Clin Oncol. 2019;37(suppl 15):TPS5600. doi:10.1200/JCO.2019.37.15_suppl.TPS5600
8. A comparison of platinum-based therapy with TSR-042 and niraparib versus standard of care (SOC) platinum-based therapy as first-line treatment of stage III or IV nonmucinous epithelial ovarian cancer (FIRST). ClinicalTrials.gov. Updated March 13, 2025. Accessed May 29, 2025. https://clinicaltrials.gov/study/NCT03602859
9. GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer. News release. GSK. December 20, 2024. Accessed May 29, 2025. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-trial-met-its-primary-endpoint-of-progression-free-survival-in-first-line-advanced-ovarian-cancer/
10. Monk BJ, Toita T, Wu X, et al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1334-1348. doi:10.1016/S1470-2045(23)00479-5
11. Mayadev J, Vázquez Limón JC, Javier F, et al. Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses. J Clin Oncol. 2025;43(suppl 16):5502. doi:10.1200/JCO.2025.43.16_suppl.5502